Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Unknown 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Melanoma 17Colorectal Neoplasms 13Carcinoma, Non-Small-Cell Lung 6Neoplasms 4Neoplasm Metastasis 4Skin Neoplasms 3Lung Neoplasms 3Gastrointestinal Neoplasms 3Rectal Neoplasms 2Digestive System Neoplasms 2Colonic Neoplasms 2Solid Tumors Harboring a BRAF V600 Mutation 1Solid Tumors 1Skin Diseases 1Rectal Diseases 1Pancreatic Neoplasms 1Neurofibromatosis 1 1Intestinal Neoplasms 1Intestinal Diseases 1Hereditary Sensory and Autonomic Neuropathies 1Hematologic Neoplasms 1Gastrointestinal Diseases 1Digestive System Diseases 1Colonic Diseases 1Brain Neoplasms 1

Interventions

Bevacizumab 9Oxaliplatin 7Irinotecan 6Fluorouracil 6Nivolumab 5Leucovorin 5Cetuximab 5Capecitabine 5pembrolizumab 4Sunitinib 4IFL protocol 4Drug Therapy 4Cisplatin 4encorafenib 3Pemetrexed 3Gemcitabine 3Folfox protocol 35,10-methylenetetrahydrofolic acid 3trebananib 2trastuzumab deruxtecan 2amminedichloro(2-methylpyridine)platinum(II) 2Ocoxin 2N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 2Levoleucovorin 2IDRX-42 2CGX1321 2130-nm albumin-bound paclitaxel 2zanidatamab 1ulixertinib 1tivozanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Gastrointestinal Neoplasms × encorafenib × Clear all
NCT05039177 2026-03-25

HERKULES-3

Erasca, Inc.

Phase 1/2 Completed
101 enrolled
Gastrointestinal

Digestive System Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04607421 2025-08-14

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Pfizer

Phase 3 Active not recruiting
831 enrolled 2 FDA
Gastrointestinal

Colonic Diseases, Colonic Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Rectal Diseases, Rectal Neoplasms, Colorectal Neoplasms

NCT02675946 2022-01-26

CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)

Curegenix Inc.

Phase 1 Unknown
72 enrolled
Gastrointestinal

Gastrointestinal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡